Bicalutamide dosages used in the treatment of prostate cancerKOLVENBAG, G. J. C. M; NASH, A.The Prostate. 1999, Vol 39, Num 1, pp 47-53, issn 0270-4137Article

Bicalutamide (Casodex®) in the treatment of prostate cancer : History of clinical developmentKOLVENBAG, G. J. C. M; BLACKLEDGE, G. R. P; GOTTING-SMITH, K et al.The Prostate. 1998, Vol 34, Num 1, pp 61-72, issn 0270-4137Article

The antiandrogen withdrawal syndrome in relapsed prostate cancerSCHER, H. I; KOLVENBAG, G. J. C. M.European urology. 1997, Vol 31, pp 3-7, issn 0302-2838, SUP2Conference Paper

Worldwide activity and safety of bicalutamide : a summary reviewKOLVENBAG, G. J. C. M; BLACKLEDGE, G. R. P.Urology (Ridgewood, NJ). 1996, Vol 47, Num 1A, pp 70-79, issn 0090-4295, SUPConference Paper

Molecular characterization of a membrane protein by a simple immunobinding procedure with monoclonal antibodiesSONNENBERG, A; KOLVENBAG, G. J. C. M; AL, E. J. M et al.Journal of immunological methods. 1984, Vol 72, Num 2, pp 443-450, issn 0022-1759Article

Defining the role of antiandrogens in the treatment of prostate cancerMCLEOD, D. G; KOLVENBAG, G. J. C. M.Urology (Ridgewood, NJ). 1996, Vol 47, Num 1A, pp 85-89, issn 0090-4295, SUPConference Paper

Three-month depot of goserelin acetate : Clinical efficacy and endocrine profileFERNANDEZ DEL MORAL, P; DIJKMAN, G. A; DEBRUYNE, F. M. J et al.Urology (Ridgewood, NJ). 1996, Vol 48, Num 6, pp 894-900, issn 0090-4295Article

Monoclonal antibodies detecting different epitopes on the Forssman glycolipid haptenSONNENBERG, A; VAN BALEN, P; HENGEVELD, T et al.The Journal of immunology (1950). 1986, Vol 137, Num 4, pp 1264-1269, issn 0022-1767Article

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockadeSCHELLHAMMER, P. F; VENNER, P; CHEN, Y et al.The Journal of urology. 1997, Vol 157, Num 5, pp 1731-1735, issn 0022-5347Article

Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? CommentarySAROSDY, M. F; SCHELLHAMMER, P. F; JOHNSON, R et al.Urology (Ridgewood, NJ). 2000, Vol 55, Num 3, pp 391-396, issn 0090-4295Article

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analoguesMCLEOD, D. G; SCHELLHAMMER, P. F; KOLVENBAG, G. J. C. M et al.The Prostate. 1999, Vol 40, Num 4, pp 218-224, issn 0270-4137Article

Comparison of goserelin and leuprolide in combined androgen blockade therapySAROSDY, M. F; SCHELLHAMMER, P. F; SCHELLENGER, J. J et al.Urology (Ridgewood, NJ). 1998, Vol 52, Num 1, pp 82-88, issn 0090-4295Article

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma : Final report of a double-blind, randomized, multicenter trialSCHELLHAMMER, P. F; SHARIFI, R; BLOCK, N. L et al.Urology (Ridgewood, NJ). 1997, Vol 50, Num 3, pp 330-336, issn 0090-4295Article

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma : Analysis of time to progressionSCHELLHAMMER, P. F; SHARIFI, R; BLOCK, N. L et al.Cancer. 1996, Vol 78, Num 10, pp 2164-2169, issn 0008-543XArticle